Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

Figures & data

Table 1. Patient characteristics at baseline (n = 31).

Patient characteristics	Median	IQR
Age	50	46–56
Age at diagnosis	32	27–35
Length of infection (years)	18	16–21
Length of antiretroviral (ARV) treatment (years)	14	12–16
CD4 nadir (cells/μl)	152	69–210
CD4 (cells/μl)	520	360–380

* IQR: interquartile range.

Table 2. Baseline drug regimen (n = 31).

Regimen at baseline	N	%
2 NRTIs+1 PI/r+1 NNRTI	8	26
2 NRTIs+1 PI/r+1 RAL	8	26
2 NRTIs+1 PI/r+1 NNRTI+1 RAL	6	19
3 NRTIs+1 PI/r+1 NNRTI	3	10
1 NRTI+1 PI/r+1 NNRTI+1 RAL	2	6
3 NRTIs+1 PI/r	2	6
2 NRTIs+2 PI/r	1	3
1 NRTI+1 PI/r+1 RAL+MVC	1	3

NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: non-nucleoside reverse-transcriptase inhibitor; PI/r: protease inhibitor (boosted with ritonavir); RAL: raltegravir; MVC: maraviroc.